Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871542 · ClinicalTrials.gov registry record
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
A clinical trial of Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- 2,062
- Enrollment target
- 6
- Study locations
NCT04871542 is a study of Malignant Solid Neoplasm that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 2,062 participants, above the 1,129-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (83% higher). The trial reports 6 study locations across 1 state.
The verdict
NCT04871542, a study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- 2,062 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
Study Locations (6)
Iowa
- Mary Greeley Medical Center - Ames
- McFarland Clinic PC - Ames - Ames
- McFarland Clinic PC-Boone - Boone
- McFarland Clinic PC-Trinity Cancer Center - Fort Dodge
- McFarland Clinic PC-Jefferson - Jefferson
- McFarland Clinic PC-Marshalltown - Marshalltown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,062 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2028-03-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04871542
The ClinicalTrials.gov registry entry for NCT04871542 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,062 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,129-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (83% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04871542 reports 6 study locations spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT04871542 about?
NCT04871542 is a clinical study titled "Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors". This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is th...
What is the current status of trial NCT04871542?
This trial is currently recruiting. The enrollment target is 2,062 participants. The study started on 2021-09-13. Estimated completion is 2028-03-14.
What conditions does trial NCT04871542 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm.
What interventions are being tested in trial NCT04871542?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT04871542?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04871542 being conducted?
This trial has 6 study locations across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
RECRUITING
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.